TY - JOUR
T1 - Overview of epstein–barr-virus-associated gastric cancer correlated with prognostic classification and development of therapeutic options
AU - De Re, Valli
AU - Brisotto, Giulia
AU - Repetto, Ombretta
AU - De Zorzi, Mariangela
AU - Caggiari, Laura
AU - Zanussi, Stefania
AU - Alessandrini, Lara
AU - Canzonieri, Vincenzo
AU - Miolo, Gianmaria
AU - Puglisi, Fabio
AU - Belluco, Claudio
AU - Steffan, Agostino
AU - Cannizzaro, Renato
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12/2
Y1 - 2020/12/2
N2 - Gastric cancer (GC) is a deadly disease with poor prognosis that is characterized by heterogeneity. New classifications based on histologic features, genotypes, and molecular phenotypes, for example, the Cancer Genome Atlas subtypes and those by the Asian Cancer Research Group, help understand the carcinogenic differences in GC and have led to the identification of an Epstein–Barr virus (EBV)-related GC subtype (EBVaGC), providing new indications for tailored treatment and prognostic factors. This article provides a review of the features of EBVaGC and an update on the latest insights from EBV-related research with a particular focus on the strict interaction between EBV infection and the gastric tumor environment, including the host immune response. This information may help increase our knowledge of EBVaGC pathogenesis and the mechanisms that sustain the immune response of patients since this mechanism has been demonstrated to offer a survival advantage in a proportion of patients with GC.
AB - Gastric cancer (GC) is a deadly disease with poor prognosis that is characterized by heterogeneity. New classifications based on histologic features, genotypes, and molecular phenotypes, for example, the Cancer Genome Atlas subtypes and those by the Asian Cancer Research Group, help understand the carcinogenic differences in GC and have led to the identification of an Epstein–Barr virus (EBV)-related GC subtype (EBVaGC), providing new indications for tailored treatment and prognostic factors. This article provides a review of the features of EBVaGC and an update on the latest insights from EBV-related research with a particular focus on the strict interaction between EBV infection and the gastric tumor environment, including the host immune response. This information may help increase our knowledge of EBVaGC pathogenesis and the mechanisms that sustain the immune response of patients since this mechanism has been demonstrated to offer a survival advantage in a proportion of patients with GC.
KW - Carcinogenesis
KW - Epstein–Barr
KW - Gastric cancer
KW - Targeted drugs
UR - http://www.scopus.com/inward/record.url?scp=85097543057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097543057&partnerID=8YFLogxK
U2 - 10.3390/ijms21249400
DO - 10.3390/ijms21249400
M3 - Review article
C2 - 33321820
AN - SCOPUS:85097543057
VL - 21
SP - 1
EP - 23
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 24
M1 - 9400
ER -